With 2 planned launches, Boehringer Ingelheim looks to make a name for itself in oncology

With 25 launches planned through 2030, Boehringer Ingelheim is gearing up for a busy few years. As a part of that, the German drugmaker is looking forward to flexing its oncology muscles with two new cancer drug launches in 2025.